Clinical trial transparency: ‘There is no one answer to what must be disclosed’

October 10, 2018

As seen on Outsourcing-Pharma.com - Posted Oct. 10, 2018 - Original Article

 By Melissa Fassbender | The FDA recently released a draft guidance address penalties for those not disclosing clinical trial results, as patients, the scientific community, and other stakeholders call for increased transparency.


Continued on Outsourcing Pharma

Previous Article
Why EU clinical trials are missing results
Why EU clinical trials are missing results

Thomas Wicks, Chief Strategy Officer at TrialScope, analyzes why about 50 percent of EU clinical trials are...

Next Article
Web-based service targets clinical trial sponsors
Web-based service targets clinical trial sponsors